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Objective: L1 cell adhesion molecule (L1CAM), as a member of the immunoglobulin superfamily, has recently been
observed in a variety of human malignancies. However, no data of L1CAM are available for hepatocellular
carcinoma (HCC). The aim of this study was to investigate the expression of L1CAM in HCC and determine its
correlation with tumor progression and prognosis.
Methods: One-hundred and thirty HCC patients who had undergone curative liver resection were selected and
immunohistochemistry, Western blotting, and quantitative real time polymerase chain reaction (Q-PCR) were
performed to analyze L1CAM expression in the respective tumors.
Results: Immunohistochemistry, Western blotting, and Q-PCR consistently confirmed the overexpression of L1CAM
in HCC tissues compared with their adjacent nonneoplastic tissues at both protein and gene level (both P <0.01).
Additionally, the high expression of L1CAM was significantly associated with advanced tumor stage (P = 0.02) and
advanced tumor grade (P = 0.03), respectively. Moreover, HCC patients with high L1CAM expression were
significantly associated with lower 5-year overall survival (P <0.01) and lower 5-year disease-free survival (P <0.01),
respectively. The Cox proportional hazards model further showed that L1CAM over-expression was an
independent poor prognostic factor for both 5-year disease-free survival (P = 0.02) and 5-year overall survival
(P = 0.008) in HCC.
Conclusion: Our data suggest for the first time that L1CAM expression in HCC was significantly correlated with
the advanced tumor progression and was an independent poor prognostic factor for both overall survival and
disease-free survival in patients with HCC.
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Hepatocellular carcinoma (HCC) is one of the most fre-
quent human malignancy worldwide. Especially in
China, it has become a major cause of cancer-related
death [1]. There are many risk factors associated with
HCC disease etiology, such as hepatitis B virus (HBV)
and hepatitis C virus (HCV) infection, genetic makeup
and environmental exposure [2]. The main features of
HCC are fast infiltrating growth, early metastasis, high-
grade malignancy, and poor therapeutic efficacy. Al-
though surgical resection is the best method to ensure
long-term survival for HCC patients, frequent recur-
rence and a high incidence of metastasis often make the
overall prognosis unsatisfactory. The progression of
HCC is associated with cumulative genomic alterations,
including oncogene upregulation and tumor suppressor
downregulation. Therefore, it is necessary to clarify the
molecular pathogenesis of HCC.
The L1 cell adhesion molecule (L1CAM, also named as
CD171), as a member of the immunoglobulin superfam-
ily, is a 220 kDa type I transmembrane glycoprotein [3].
It is comprised of six IgG-like domains and five
fibronectin-type III repeats, followed by a transmem-
brane region and a highly conserved cytoplasmic tail [4].
L1CAM was first described in neural cell migration [5].
Then, several studies demonstrated that this protein
plays pivotal roles in mediating the correct formation of
neuronal connections during embryo neurogenesis and
performs important functions in neuron-neuron adhe-
sion, neurite fasciculation, synaptogenesis, neurite out-
growth on Schwann cells, and neuronal cell migration
[6-8]. In other normal cells such as hematopoietic, endo-
thelial, and intestinal crypt cells, L1CAM is also detected,
however, its function is unclear [9,10]. Recent studies
have found the association of L1CAM expression with
various human malignancies by analysis using established
cell lines, and fresh frozen or fixed paraffin-embedded
tissues. As the results, L1CAM expression was observed
in lung cancer cell lines, gallbladder carcinomas, colon
cancer, pancreatic cancer, renal cell cancer, gliomas, ovar-
ian carcinomas, endometrial carcinomas, and melanomas
[11-15]. However, no data of L1CAM are available for
HCC. The aim of this study was to investigate the expres-
sion of L1CAM in HCC and determine its correlation
with tumor progression and prognosis.Materials and methods
Patients and tissue samples
The study was approved by the Research Ethics Commit-
tee of 302nd Hospital of PLA, Beijing, China. Informed
consent was obtained from all of the patients. All speci-
mens were handled and made anonymous according to
the ethical and legal standards.A total of 130 patients with primary HCC who under-
went a curative liver resection at the 302nd Hospital of
PLA, Beijing, China, were included in this retrospective
study. Tissues used in the study were retrieved from the
tissue bank of the Department of Pathology in the 302nd
Hospital of PLA. These patients were diagnosed as HCC
between 2001 and 2006. None of the patients recruited
in this study had chemotherapy or radiotherapy before
the surgery. HCC diagnosis was based on World Health
Organization (WHO) criteria. Tumor differentiation was
defined according to the Edmondson grading system.
Liver function was assessed using the Child-Pugh scor-
ing system. Tumor staging was determined according to
the sixth edition of the tumor-node-metastasis (TNM)
classification of the International Union against Cancer.
No distant metastasis was present at the time of surgery.
The clinicopathological features of 130 patients are sum-
marized in Table 1.
The median follow-up period was 8.6 years. Postopera-
tive surveillance included routine clinical and laboratory
examinations every third month, computed tomography
scans of the abdomen, and radiographs of the chest
every third month. After 5 years, the examination inter-
val was extended to 12 months.
Immunohistochemistry analysis
Immunohistochemical staining was carried out follow-
ing the protocol of our previous study [16]. The pri-
mary antibody against L1CAM: mouse monoclonal
antibody against the human ectodomain of L1 (UJ127,
cat.#GTX72362; Gene Tex, Irvine, CA, dilution 1:500).
The specificity of the primary antibody has been demon-
strated by several previous studies [11,13,14]. Secondary
antibody for the detection of primary antibody: anti-
mouse IgG (Sigma, St. Louis, MO, USA). The negative
controls were processed in a similar manner with PBS
instead of primary antibody. Further, positive L1CAM
expression confirmed by western blotting was used as
positive controls for immunostaining.
Following a hematoxylin counterstaining, immunos-
taining was scored by two independent experienced
pathologists, who were blinded to the clinicopathological
parameters and clinical outcomes of the patients. The
scores of the two pathologists were compared and any
discrepant scores were trained through re-examining the
stainings by both pathologists to achieve a consensus
score. The number of positive-staining cells showing
immunoreactivity on the membrane for L1CAM in ten
representative microscopic fields was counted and the
percentage of positive cells was calculated. The percent-
age scoring of immunoreactive tumor cells was as fol-
lows: 0 (0%), 1 (1-10%), 2 (11-50%) and 3 (>50%). The
staining intensity was visually scored and stratified as fol-
lows: 0 (negative), 1 (weak), 2 (moderate) and 3 (strong).
Table 1 Clinicopathological features and the expression of L1CAM in 130 HCC patients
Clinicopathological Features Case L1CAM expression frequency (n,%) P
High Low
Age (years)
≤50 72 45 (63.13) 27 (23.61) 0.6
>50 58 37 (63.79) 21 (25.86)
Gender
Male 96 62 (64.58) 34 (35.42) 0.5
Female 34 20 (58.82) 14 (41.18)
Tumor stage
T1 23 5 (21.74) 18 (78.26)
T2 40 12 (30.00) 28 (70.00) 0.02
T3 52 50 (96.15) 2 (3.85)
T4 15 15 (100.00) 0 (0)
Tumor grade
G1 31 4 (12.90) 27 (77.10)
G2 76 55 (72.37) 21 (27.63) 0.03
G3 23 23 (100.00) 0 (0)
Growth pattern
Trabecular 101 62 (61.39) 39 (38.61) 0.6
Nontrabecular 29 20 (68.97) 9 (31.03)
Cirrhosis
Yes 86 56 (65.12) 30 (34.88) 0.5
No 44 26 (59.09) 18 (40.91)
Underlying liver disease
Alcoholic 25 18 (72.00) 7 (28.00)
Hepatitis B 49 40 (81.63) 9 (18.37) 0.3
Hepatitis C 35 12 (34.29) 23 (65.71)
Unknown 21 12 (57.14) 9 (42.86)
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the percentage and the intensity score. Therefore, tumors
with a multiplied score exceeding 4 (median of total
scores for L1CAM) were deemed to be low expressions
of L1CAM; all other scores were considered to be high
expressions of L1CAM.Western blot
The Western blot protocol and semiquantitative analysis
were carried out following the protocol of Xu et al. [17].
L1CAM antibody (mouse monoclonal antibody, dilution
1:1000, Santa Cruz Biotechnology, Inc. USA) was used,
and GAPDH antibody (CW0266, dilution 1:1,000,
CoWin Biotech) was used as internal control.Quantitative RT-PCR
To measure the mRNA expression levels of L1CAM,
total RNA was extracted from frozen liver tissues using
TriZol reagent (Invitrogen) following the manufacturer’s
instructions. Two micrograms of total RNA was subjectedto reverse transcription to synthesize cDNA using the
ProtoScript M-MuLV Taq RT-PCR Kit (New England
Biolabs), according to the manufacture’s instruction, fol-
lowed by real-time PCR using the TransStart Green qPCR
SuperMix (TransGen Biotech). The primer sequences of
L1CAM were forward primer, 50- ACG AGG GAT GGT
GTC CAC TTC AAA-30, reverse primer, 50- TTA TTG
CTG GCA AAG CAG CGG TAG-30. The transcription of
GAPDH was used as an internal control for normalization.
L1CAM expression levels were calculated relative to
GAPDH using the delta-delta computed tomography
method [18].
Statistical analysis
The software of SPSS version13.0 for Windows (SPSS
Inc, IL, USA) and SAS 9.1 (SAS Institute, Cary, NC) was
used for statistical analysis. Fisher’s exact test and the X2
test were performed to assess associations between
L1CAM expression and clinicopathological parameters.
The Kaplan-Meier method was used for survival ana-
lysis, and differences in survival were estimated using
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performed for all parameters that were significant in the
univariate analyses using the Cox regression model. Dif-
ferences were considered statistically significant when P
was less than 0.05.
Results
Expression of L1CAM protein and mRNA in HCC
To analyze the clinical value of L1CAM in HCC, we first
evaluated its expression at protein and mRNA levels by
immunohistochemical analysis, western blot analysis and
quantitative RT-PCR.
As the results, the immunostaining was homogeneous
throughout the tumor. L1CAM immunostaining was
mainly localized on the membrane of tumor cells of
HCC tissues (Figure 1A). L1CAM expression was absent
or sporadic in adjacent nonneoplastic liver tissues
(Figure 1B). In addition, we found 82 (63.08%) of 130
HCC tissues with high L1CAM expression and 48
(36.92%) of 130 HCC tissues with low L1CAM expres-
sion, while all the adjacent nonneoplastic liver tissues
with low L1CAM expression. Thus, the L1CAM immu-
nostainings in HCC tissues were significantly higher
than those in the adjacent nonneoplastic liver tissues
(P <0.01).
Additionally, Western blot analysis as an independent
method was performed to confirm L1CAM protein ex-
pression. The distinct overexpression of L1CAM protein
in HCC tissues compared with adjacent nonneoplastic
liver tissues was also detected (P <0.01, Figure 2A and
B), as well as significantly increased mRNA level by
quantitative RT-PCR (P <0.01, Figure 2C).
Association of L1CAM expression with the
clinicopathological features of HCC
We next evaluated whether L1CAM protein expres-
sion was associated with clinicopathological features of
patients with HCC by correlating immunohistochemicalFigure 1 Immunohistochemical staining of L1CAM expression in hepa
tissues (Original magnification × 400). A, L1CAM positive staining was in
HCC cells; B, L1CAM negative staining was seen in adjacent nonneoplasticL1CAM staining results with T stage, tumor grade,
presence of cirrhosis, underlying liver disease including
alcohol abuse, viral hepatitis B and C, sex, and age
(Table 1). As the results, we found that the high expres-
sion of L1CAM was significantly associated with
advanced tumor stage (P = 0.02) and advanced tumor
grade (P = 0.03), respectively.
Prognostic values of L1CAM expression in HCC
To further investigate the clinical usefulness of L1CAM
expression in HCC, we compared five-year overall sur-
vival and five-year disease-free survival according to
various clinicopathologic factors including the expres-
sion level of L1CAM. Five-year disease-free survival was
observed in 30 (23.08%) patients, whereas in 100
(76.92%) patients, disease recurred, and 88 (67.69%) even
died during a 5-year follow-up period. We observed a
trend that 5-year disease-free survival in the group with
high L1CAM expression was significantly poorer than
that in the group with low L1CAM expression (P <0.01,
log-rank test; Figure 3A). Additionally, the Kaplan-Meier
plot of 5-year overall survival curves stratified by
L1CAM expression was shown in Figure 3B. A signifi-
cant relationship was found between L1CAM expression
and 5-year overall survival (P <0.01, log-rank test,
Figure 3B). Futhermore, in a multivariate Cox model, in-
cluding tumor size, tumor stage, tumor grading, pres-
ence of cirrhosis, gender, age, and L1CAM staining, we
found that L1CAM expression was an independent poor
prognostic factor for both 5-year disease-free survival
(hazards ratio [HR] = 2.279, 95% confidence interval
[CI] = 1.185-5.697, P = 0.02, Table 2) and 5-year overall
survival (HR= 3.269, CI = 1.136-7.328, P = 0.008, Table 2)
in HCC.
Discussion
In this study, we first dmonstrate that L1CAM protein
and mRNA expression in human HCC tissue wastocellular carcinoma (HCC) and adjacent nonneoplastic liver
dicated by numerous yellowish granules in the membrane of
liver tissues.
Figure 2 Increased expression levels of L1CAM protein and mRNA in hepatocellular carcinoma (HCC) and adjacent nonneoplastic liver
tissues. (A) Representative Western blotting of L1CAM protein levels in HCC tissues and adjacent nonneoplastic liver tissues. (B) Semiquantitative
Western blotting showed significantly increased L1CAM protein level in HCC tissues compared with adjacent nonneoplastic liver tissues.
GAPDH was used as internal control. Means, standard deviation (SD), and P values were given (T test). (C) Significantly increased L1CAM mRNA
level (P <0.01, Mann–Whitney test) in HCC tissues compared with adjacent nonneoplastic liver was detected by quantitative RT-PCR. GAPDH was
used as internal control.
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icopathologic features. Immunohistochemical analysis of
a large set of HCCs revealed that 63.08% of HCC were
high expression for L1CAM. Notably, L1CAM immu-
noreactivity was distinctly increased in a substantial pro-
portion of HCC cases compared with their adjacent
nonneoplastic liver tissue, which was further confirmed
by Western bloting analysis and Q-PCR analysis. Then,
the expression of L1CAM in HCC tissues with advancedFigure 3 Kaplan-Meier survival curves for L1CAM expression in the H
significantly shorter disease-free survival (P <0.01, A) and overall survival (Ptumor stage and grade was significantly higher than that
in early tumor stage and low tumor grade HCC, suggest-
ing that L1CAM expression might be of clinical rele-
vance in the aggressiveness of HCC. The impact of
L1CAM expression on clinical outcome was assessed by
Kaplan-Meier analyses. High L1CAM expression was
associated with a significant trend toward both poorer
disease-free and overall survival. Univariate and multi-
variate analyses clearly demonstrated that L1CAMCC patients. The HCC patients with high L1CAM expression showed
<0.01, B) rates than those with low L1CAM expression.
Table 2 Multivariate survival analysis of five-year overall and disease-free survival in 130 patients with HCC
Features Five-year overall survival Five-year disease-free survival
HR 95% CI P HR 95% CI P
Age 1.132 0.316-3.516 0.192 1.536 0.322-3.736 0.125
Gender 1.191 0.345-3.857 0.136 1.559 0.357-3.831 0.131
Tumor size 1.931 0.685-4.056 0.063 1.953 0.615-4.273 0.062
Tumor stage 2.879 1.366-5.196 0.009 2.686 1.386-6.009 0.01
Tumor grade 1.563 0.609-4.088 0.081 1.551 0.607-4.466 0.086
Presence of cirrhosis 1.919 0.738-4.102 0.063 1.921 0.793-4.219 0.062
L1CAM expression 3.269 1.136-7.328 0.008 2.279 1.185-5.697 0.02
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overall survival and disease-free survival of patients with
HCC. The statistically significant impact of L1CAM ex-
pression for overall survival (P = 0.008) was more signifi-
cant than the tumor stage (P = 0.009) that is widely used
at present, suggesting that L1CAM expression could be
a useful marker to predict patient survival.
It is necessary to identify biological markers associated
with the advancement of tumor progression for early
diagnosis of patients with aggressive tumors and poor
prognosis, and for the development of new therapeutic
strategies and the selection of the appropriate treatment.
The cell dhesion molecule families, such as integrins,
cadherins, immunoglobulin-like CAMs and selectins, are
often aberrantly regulated in human malignancies, lead-
ing to the tumor progression [19]. L1CAM, a member of
immunoglobulin-like CAMs, was first reported to be
involved in human cancers by investigating its expres-
sion in B16 melanoma cells [20]. After that, L1CAM
overexpression has been found in various other tumors.
Especially in degestive system, the study of Issa et al.
[21] observed that L1CAM expression was selectively
enhanced on endothelium associated with pancreatic
adenocarcinoma in situ and on cultured pancreatic
tumor-derived endothelial cells in vitro; Kodera et al.
[22] detected the expression of L1CAM in gastric cancer
specimens, more often among the intestinal-type cancer,
and further demonstrated the prognositc value of
L1CAM expression in pT3-stage gastric cancer; Choi
et al. [23] also indicated that L1CAM was not expressed
in the normal epithelium of the gallbladder but in 63.8%
of gallbladder carcinomas, remarkably at the invasive
front of the tumors; regarding the clinical significance,
they demonstrated that L1CAM expression was signifi-
cantly associated with the aggressiveness and poor prog-
nosis of gallbladder carcinomas. With the similar results
of these previous studies, our data also shown the asso-
ciation of L1CAM overexpression with the advancement
and short survival of HCC patients.
The function of L1CAM determines its contribution
to the tumorigensis. At first, L1CAM is a target gene ofβ-catenin-TCF signaling, which is an important cancer-
related pathway. Many β-catenin target genes including
metalloproteases, cell-extracellular matrix components,
transcription factors, and cell adhesion molecules have
been demonstrated to be involved in later stages of
tumorigenesis that can confer invasive and metastatic
capacities [24]. In 2006, Huszar et al. [25] identified
L1CAM as a novel target gene of β-catenin-TCF signal-
ing which is implicated in human colon cancer develop-
ment. LEF/TCF binding sites were detected in the
L1CAM promoter and an inducible dominant negative
TCF, or an siRNA to β-catenin, suppressed the expres-
sion of L1CAM in colon cancer cells [26]. In addition,
L1CAM induces ERK activation and ERK-regulated
genes, including various integrin genes associated with
cell motility and invasion. It was linked to activation of
ERK and focal adhesion kinase to apoptosis protection
in ovarian carcinoma [27]. Thirdly, L1CAM does not
only mediate homophilic binding between cells, but also
forms heterophilic interactions with various ECM pro-
teins and their receptors. The L1CAM-induced cell mo-
tility was shown to involve a direct interaction of the
shed L1CAM ectodomain, or the full-length L1CAM,
with integrins, implying that L1CAM may play a role in
cancer promotion and metastasis by also mediating cell-
ECM interactions [28]. Because of its involvement in a
wide variety of human cancers, L1CAM has been con-
sidered as a target molecule for cancer therapeutics. For
example, the study of Bao et al. [29] found that L1CAM
is required for maintaining the growth and survival of
CD133+ glioma cells both in vitro and in vivo, and
L1CAM may represent a cancer stem cell specific thera-
peutic target for improving the treatment of malignant
gliomas and other brain tumors; Hung et al. [30]
reported that targeting L1CAM using lentivirus-
mediated shRNA may be a useful molecular pharma-
ceutical approach for the treatment of advanced oral
squamous cell carcinoma; These previous studies sug-
gested that using L1CAM as a drug target might im-
prove the cancer patients’ outcome. The value of
L1CAM in HCC therapy also needs further evaluation.
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pressed in HCC tissues compared with their benign
counterparts. To the best our knowledge, this is the first
study evaluating the expression levels of L1CAM mRNA
and protein in HCC tissues and its association with clin-
icopathologic parameters. Especially, the most important
finding of this study is that L1CAM also is a novel and
potential factor for predicting the poorer prognosis of
HCC patients after surgery.
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